Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy

Rationale: Current traditional treatment options are frequently ineffective to fight against ovarian cancer due to late diagnosis and high recurrence. Therefore, there is a vital need for the development of novel therapeutic agents. B7H3, an immune checkpoint protein, is highly expressed in various...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Cheng, Li, Hongjian, Feng, Yunyu, Li, Xiaoling, Zhang, Zongliang, Jiang, Caiying, Wang, Jichao, Yang, Chenli, Fu, Yuying, Mu, Min, Zhao, Shasha, Wang, Zeng, Kuang, Yi, Hou, Huan, Wang, Yuelong, Guo, Wenhao, Xu, Jianguo, Yang, Hui, Zhou, Liangxue, Tong, Aiping, Guo, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482810/
https://www.ncbi.nlm.nih.gov/pubmed/32929362
http://dx.doi.org/10.7150/thno.49480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482810/
https://www.ncbi.nlm.nih.gov/pubmed/32929362
http://dx.doi.org/10.7150/thno.49480

Ejemplares similares